Longeveron is a clinical-stage biotechnology company in Miami, Florida developing allogeneic cellular therapies for life-threatening and aging-related conditions in children and the elderly. Its lead investigational product, Lomecel-B (laromestrocel), is a bone marrow-derived medicinal signaling cell (MSC) therapy manufactured in the company's own Miami cell processing facility. Lomecel-B is in clinical development for hypoplastic left heart syndrome, pediatric dilated cardiomyopathy, Alzheimer's disease, and age-related frailty. The company trades on Nasdaq under the ticker LGVN.